#1 - Pfizer (NYSE:PFE)
We understand that starting with Pfizer (NYSE:PFE) may be off-putting to some investors. The company is polarizing, to say the least. However, as the omicron variant reminds us, the pandemic may be closer to an end than the beginning, but it still has some chapters to go. That means that Pfizer is likely to continue to generate strong revenue and earnings.
PFE stock is up 42% in 2021 easily outpacing the S&P 500 and to be fair the consensus price target of analysts tracked by MarketBeat shows the stock trading has peaked. However, the company released its last earnings report prior to the discovery of the omnicron variant. Since then, the stock has received several raised price targets from analysts.
And this bullish view is supported by Dan Ushman, CEO and Founder of the technical analysis software firm TrendSpider who believes PFE stock is displaying a strong technical outlook. In a research note, Ushman noted that PFE stock recently broke through a level of resistance and is now trading at an all-time high. Ushman believes that Pfizer may retest recent lows, but if it can stay above those levels it could break out to the upside.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More - Current Price
- $24.97
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $32.92 (31.9% Upside)
